San Antonio, Texas — According to state and local development sources, Scorpius BioManufacturing plans to invest $2,093,748.00 to build out 5,648 square feet of new space in San Antonio. The company plans to occupy the new space at 1305 E. Houston, Suite 1106 in San Antonio, on or about December 1, 2024. According to the company website Scorpius BioManufacturing is a CDMO focused on mammalian, microbial, and cell therapies. We provide a broad array of biologics manufacturing, analytical and R&D services to pharmaceutical and biotech companies to advance their discoveries and deliver new therapies to patients from our San Antonio facilities, with a focus on offering services using American-made equipment, reagents, and materials. Our biomanufacturing services focus on accelerating product development timelines from pre-clinical evaluation to first-in-human studies and beyond in support of commercial manufacturing programs. By integrating analytical methods development, process development, cGMP manufacturing product characterization, and QC release testing, we can efficiently develop a client-specific clinical manufacturing solution that enables a faster path to clinical trials and product commercialization.

To learn more about Scorpius BioManufacturing, visit http://www.scorpiusbiologics.com/

Company Contact:
Jeff Wolf, Chief Executive Officer
jwolf@scorpiusbiologics.com
726-201-5050

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.